Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6098429 | 1.00 | PDE2A (0.46) | PDE2AKCNH2HTTLMNATP53 | |
| SCHEMBL29924355 | 1.00 | PDE2A (0.46) | PDE2AKCNH2HTTLMNATP53 | |
| SCHEMBL30399466 | 1.00 | PDE2A (0.46) | PDE2AKCNH2HTTLMNATP53 | |
| SCHEMBL17215353 | 1.00 | PDE2A (0.46) | PDE2AKCNH2HTTLMNATP53 | |
| SCHEMBL23489755 | 0.85 | KCNH2 (0.46) | PDE2AKCNH2HTTLMNATP53 | |
| SCHEMBL20238442 | 0.85 | KCNH2 (0.46) | PDE2AKCNH2HTTLMNATP53 | |
| SCHEMBL20238444 | 0.85 | KCNH2 (0.46) | PDE2AKCNH2HTTLMNATP53 | |
| SCHEMBL84107 | 0.83 | LMNA (0.47) | PDE2AKCNH2HTTLMNATP53 | |
| SCHEMBL1350237 | 0.83 | KCNH2 (0.45) | PDE2AKCNH2HTTLMNATP53 | |
| SCHEMBL22852398 | 0.83 | KCNH2 (0.45) | PDE2AKCNH2HTTLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590081-B2 | Fused imidazole derivatives, preparation method and medicinal use thereof | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2026-03-31 | — | — | US | disclosed |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | TAY THERAPEUTICS LTD (GB) | 2026-01-01 | — | — | US | disclosed |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-08-21 | — | — | US | disclosed |
| EP-4558224-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-05-28 | — | — | EP | disclosed |
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| WO-2024138048-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240199620-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
| WO-2024018423-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2024-01-25 | — | — | WO | disclosed |
| US-11702404-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702404-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20110301211-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20110301142-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| CN-102245584-A | Antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS INC | 2011-11-16 | — | — | CN | disclosed |
| US-8048902-B2 | Antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| EP-2358688-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20110196005-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC., (US) | 2011-08-11 | — | — | US | disclosed |
| WO-2010077882-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077883-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100152257-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| CN-1894213-A | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | MERCK & CO INC (CA) | 2007-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | PDE2A 111/4885KCNH2 1883/4885HTT 250/4885 |
| US-20100152257-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | PDE2A 1591/4885KCNH2 3461/4885HTT 3033/4885 |
| US-11702404-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | PDE2A 130/4885KCNH2 3295/4885HTT 806/4885 |
| US-12590081-B2 | Fused imidazole derivatives, preparation method and medicinal use thereof | GLP1R, GIPR, GPR119 | PDE2A 235/4885KCNH2 454/4885HTT 1253/4885 |
| US-20110196005-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | PDE2A 1591/4885KCNH2 3461/4885HTT 3033/4885 |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, BRD4, PHKB | PDE2A 3114/4885KCNH2 2272/4885HTT 2778/4885 |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, PHKB, BRD4 | PDE2A 3629/4885KCNH2 4652/4885HTT 1428/4885 |
| US-20110301211-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | PDE2A 1591/4885KCNH2 3461/4885HTT 3033/4885 |
| US-20240199620-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | CCR4, CCR1, CCR3 | PDE2A 767/4885KCNH2 4825/4885HTT 4810/4885 |
| US-20110301142-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | PDE2A 1591/4885KCNH2 3461/4885HTT 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.